Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.49 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.42 |
| ▸ | SCARB1 | Q8WTV0 | 9/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22705390 | 0.88 | MAPK14 (0.46) | MAPK14CXCL8SCARB1HPGDLMNA | |
| SCHEMBL17669692 | 0.87 | MAPK14 (0.45) | MAPK14SCARB1BRAF | |
| SCHEMBL1846611 | 0.86 | MAPK14 (0.63) | MAPK14SCARB1BRAF | |
| SCHEMBL29639452 | 0.84 | MAPK14 (0.50) | MAPK14CXCL8SCARB1HPGDKDM4E | |
| SCHEMBL28271209 | 0.84 | MAPK14 (0.50) | MAPK14CXCL8SCARB1HPGDKDM4E | |
| SCHEMBL19047465 | 0.83 | HPGD (0.43) | MAPK14CXCL8SCARB1HPGDLMNA | |
| SCHEMBL20541046 | 0.83 | MAPK14 (0.42) | MAPK14CXCL8SCARB1ALDH1A1MAPT | |
| SCHEMBL17552257 | 0.82 | MAPK14 (0.44) | MAPK14CXCL8SCARB1HPGDLMNA | |
| SCHEMBL19434576 | 0.81 | MAPK14 (0.54) | MAPK14SCARB1BRAF | |
| SCHEMBL17996193 | 0.80 | PSIP1 (0.43) | MAPK14SCARB1HPGDLMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3440073-B1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LTD (GB) | 2022-06-08 | — | — | EP | disclosed |
| US-10941115-B2 | Kinase inhibitors | OXULAR ACQUISITIONS LIMITED (GB) | 2021-03-09 | — | — | US | disclosed |
| US-20190330155-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| US-10442828-B2 | Kinase inhibitors | TOPIVERT PHARMA LIMITED (GB) | 2019-10-15 | — | — | US | disclosed |
| US-10392346-B2 | Kinase inhibitors | TOPIVERT PHARMA LIMITED (GB) | 2019-08-27 | — | — | US | disclosed |
| EP-3440073-A1 | KINASE INHIBITORS | Topivert Pharma Limited (GB) | 2019-02-13 | — | — | EP | disclosed |
| US-10125100-B2 | Kinase inhibitors | RESPIVERT LIMITED | 2018-11-13 | — | — | US | disclosed |
| US-20180319748-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2018-11-08 | — | — | US | disclosed |
| US-20180305383-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2018-10-25 | — | — | US | disclosed |
| US-10072034-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-09-11 | — | — | US | disclosed |
| US-20170291917-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| WO-2017174995-A1 | KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
| US-20170253563-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2017-09-07 | — | — | US | disclosed |
| US-9751837-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-09-05 | — | — | US | disclosed |
| US-20160102059-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072034-B2 | Kinase inhibitors | SYK, LYN, BTK | MAPK14 86/4885CXCL8 1510/4885SCARB1 928/4885 |
| US-20180305383-A1 | KINASE INHIBITORS | SYK, LTK, LTB4R | MAPK14 111/4885CXCL8 1148/4885SCARB1 328/4885 |
| US-10442828-B2 | Kinase inhibitors | SYK, LTK, LTB4R | MAPK14 111/4885CXCL8 1148/4885SCARB1 328/4885 |
| US-20180319748-A1 | KINASE INHIBITORS | LYN, SYK, BTK | MAPK14 96/4885CXCL8 1367/4885SCARB1 567/4885 |
| US-10125100-B2 | Kinase inhibitors | SYK, LYN, SRC | MAPK14 103/4885CXCL8 1203/4885SCARB1 744/4885 |
| US-20190330155-A1 | KINASE INHIBITORS | SYK, LYN, BTK | MAPK14 118/4885CXCL8 1100/4885SCARB1 786/4885 |
| US-10941115-B2 | Kinase inhibitors | SYK, LYN, BTK | MAPK14 118/4885CXCL8 1100/4885SCARB1 786/4885 |
| US-20170291917-A1 | KINASE INHIBITORS | SYK, LYN, BTK | MAPK14 86/4885CXCL8 1510/4885SCARB1 928/4885 |
| US-20160102059-A1 | KINASE INHIBITORS | SYK, LYN, BTK | MAPK14 120/4885CXCL8 1195/4885SCARB1 750/4885 |
| US-20170253563-A1 | KINASE INHIBITORS | SYK, LYN, SRC | MAPK14 103/4885CXCL8 1203/4885SCARB1 744/4885 |
| US-10392346-B2 | Kinase inhibitors | LYN, SYK, BTK | MAPK14 96/4885CXCL8 1367/4885SCARB1 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.